Quantitation of B-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy

被引:57
作者
Cuffari, C
Seidman, EG
Latour, S
Theoret, Y
机构
[1] UNIV MONTREAL,HOP ST JUSTINE,DEPT PEDIAT,DIV GASTROENTEROL,MONTREAL,PQ H3T 1C5,CANADA
[2] UNIV MONTREAL,HOP ST JUSTINE,DEPT PEDIAT,DIV NUTR,MONTREAL,PQ H3T 1C5,CANADA
[3] UNIV MONTREAL,HOP ST JUSTINE,DEPT PHARMACOL,MONTREAL,PQ H3T 1C5,CANADA
关键词
HPLC; inflammatory bowel disease; 6-mercaptopurine metabolism;
D O I
10.1139/cjpp-74-5-580
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The effects of 6-mercaptopurine (6MP) in inflammatory bowel disease are believed to be primarily mediated by its metabolite 6-thioguanine (6TG). Our aim was to develop an assay for measuring leukocyte DNA 6TG levels in patients with Crohn's disease, and to correlate them with levels of 6TG in erythrocytes. Heparinized blood was obtained from 15 adolescent Crohn's disease patients receiving 6MP at an average dose of 1.3 mg . kg(-1). day(-1) (range 0.8-1.6 mg . kg(-1). day(-1)) for a mean of 23.7 months (range 3-71 months). Leukocyte DNA and erythrocyte 6TG levels were measured by an HPLC assay. Leukocyte 6TG levels ranged from 100 to 2305 pmol/mg DNA, while erythrocyte 6TG levels ranged from 64 to 1038 pmol/8 x 10(8) red blood cells, demonstrating significant interpatient variability. Leukocyte DNA 6TG levels correlated directly with erythrocyte 6TG levels, as measured by the Spearman rank correlation coefficient (p<0.05). The HPLC measurement of erythrocyte and leukocyte DNA 6TG levels can be useful clinically in monitoring compliance, as well as perhaps to tailor drug metabolite levels to achieve the desired clinical effect.
引用
收藏
页码:580 / 585
页数:6
相关论文
共 20 条
[1]
BOSTROM B, 1993, AM J PEDIAT HEMATOL, V15, P80
[2]
THE EFFECT OF 6-MERCAPTOPURINE ON NATURAL KILLER-CELL ACTIVITIES IN CROHNS-DISEASE [J].
BROGAN, M ;
HISERODT, J ;
OLIVER, M ;
STEVENS, R ;
KORELITZ, B ;
TARGAN, S .
JOURNAL OF CLINICAL IMMUNOLOGY, 1985, 5 (03) :204-211
[3]
CHRISTIE NT, 1986, CANCER RES, V44, P3665
[4]
CURRARI C, 1996, IN PRESS GUT
[5]
ALTERED MERCAPTOPURINE METABOLISM, TOXIC EFFECTS, AND DOSAGE REQUIREMENT IN A THIOPURINE METHYLTRANSFERASE-DEFICIENT CHILD WITH ACUTE LYMPHOCYTIC-LEUKEMIA [J].
EVANS, WE ;
HORNER, M ;
CHU, YQ ;
KALWINSKY, D ;
ROBERTS, WM .
JOURNAL OF PEDIATRICS, 1991, 119 (06) :985-989
[6]
CONCURRENT UNILATERAL CHROMATID DAMAGE AND DNA STRAND BREAKAGE IN RESPONSE TO 6-THIOGUANINE TREATMENT [J].
FAIRCHILD, CR ;
MAYBAUM, J ;
KENNEDY, KA .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (20) :3533-3541
[7]
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY OF HUMAN RED-BLOOD-CELL THIOPURINE METHYLTRANSFERASE ACTIVITY [J].
LENNARD, L ;
SINGLETON, HJ .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 661 (01) :25-33
[8]
THE CLINICAL-PHARMACOLOGY OF 6-MERCAPTOPURINE [J].
LENNARD, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (04) :329-339
[9]
GENETIC-VARIATION IN RESPONSE TO 6-MERCAPTOPURINE FOR CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
LENNARD, L ;
LILLEYMAN, JS ;
VANLOON, J ;
WEINSHILBOUM, RM .
LANCET, 1990, 336 (8709) :225-229
[10]
CHILDHOOD LEUKEMIA - A RELATIONSHIP BETWEEN INTRACELLULAR 6-MERCAPTOPURINE METABOLITES AND NEUTROPENIA [J].
LENNARD, L ;
REES, CA ;
LILLEYMAN, JS ;
MADDOCKS, JL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (04) :359-363